SCHEMBL2479783

SCHEMBL2479783

O=C(O)[C@H](c1ccccc1)N(Cc1ccccc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
LMNA P02545 5/20 0.49
ALDH1A1 P00352 2/20 0.49
POLB P06746 1/20 0.49
HSD17B10 Q99714 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MDM2 Q00987 1/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.43
SRC P12931 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
MAPK1 P28482 1/20 0.42
EPHX1 P07099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29018886 1.00 MEN1 (0.51) MEN1KMT2ALMNAALDH1A1POLB
SCHEMBL17765014 0.85 TRPM8 (0.54) MEN1KMT2ALMNAALDH1A1POLB
SCHEMBL6118841 0.85 MEN1 (0.47) MEN1KMT2ALMNAALDH1A1POLB
SCHEMBL1205835 0.82 KMT2A (0.50) MEN1KMT2ALMNAALDH1A1POLB
SCHEMBL27601264 0.81 NR4A2 (0.53) MEN1KMT2ALMNAALDH1A1POLB
SCHEMBL18586587 0.81 CYP2D6 (0.43) LMNAALDH1A1MDM2CYP1A2CYP2D6
SCHEMBL8165661 0.78 FOLH1 (0.58) MEN1KMT2AALDH1A1HSD17B10CYP1A2
SCHEMBL18586590 0.78 CYP2D6 (0.43) MEN1KMT2ALMNAALDH1A1CYP1A2
SCHEMBL16412300 0.77 DPP7 (0.56) NPC1
SCHEMBL16412301 0.77 DPP7 (0.56) NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1607090-B1 Asimadoline for the treatment of irritable bowel syndrome TIOGA PHARMACEUTICALS INC (US) 2011-10-12 EP disclosed
EP-1607090-A1 Asimadoline for the treatment of irritable bowel syndrome MERCK PATENT GmbH (DE) 2005-12-21 EP disclosed
EP-1073634-B1 METHOD FOR PRODUCING ENANTIOMERICALLY PURE N-METHYL-N- (1S)-1-PHENYL- 2-((3S)- 3-HYDROXYPYRROLIDINE- 1-YL)ETHYL]- 2,2-DIPHENYL ACETAMIDE MERCK PATENT GMBH (DE) 2005-08-31 EP disclosed
US-6344566-B1 AMIDATION AND REDUCTION AND CONVERSION WITH ACID; ASIMADOLINE MERCK PATENT GMBH (DE) 2002-02-05 US disclosed
EP-1073634-A1 METHOD FOR PRODUCING ENANTIOMER-FREE N-METHYL-N- (1S)-1-PHENYL- 2-((3S)- 3-HYDROXYPYRROLIDINE- 1-YL)ETHYL]- 2,2-DIPHENYL ACETAMIDE MERCK PATENT GmbH (DE) 2001-02-07 EP disclosed
WO-1999054298-A1 METHOD FOR PRODUCING ENANTIOMER-FREE N-METHYL-N- [(1S)-1-PHENYL- 2-((3S)- 3-HYDROXYPYRROLIDINE- 1-YL)ETHYL]- 2,2-DIPHENYL ACETAMIDE MERCK PATENT GMBH (DE) 1999-10-28 WO disclosed